# Rewired Metabolism Regulates Vessel Normalization and Immunosuppression

> **NIH NIH R01** · BAYLOR COLLEGE OF MEDICINE · 2020 · $618,327

## Abstract

Project Summary
 Multiple hallmarks distinguish tumors from their normal counterparts. Among these are escape of
immune-surveillance and aberrant metabolism (increased glycolysis). Each of these hallmarks has been
extensively investigated. Significant progress has been made, especially with the recent emergence of anti-
immune checkpoint therapies. However, these therapies still benefit a subset of patients, with efficacy seen
only in few cancer types. This reflects the heterogeneity seen between tumors that constantly evolve
resistance mechanisms to promote tumor progression. In collaboration with Dr. Sreekumar our long-term goal
is to overcome treatment resistance and metastasis in breast and other cancers by integrating our expertise in
the areas of tumor immunology and metabolism. In this context, our metabolomics data coupled with follow up
studies have highlighted the importance of tryptophan metabolism especially the kynurenine axis in regulating
tumor immune interactions. Among the kynureine pathway enzymes, we identified Kynurenine Amino
Transferase (AADAT) to be elevated in aggressive basal like tumors and significantly associated with poor
clinical outcome in patients and negatively associated with patient’s response to immune therapy in melanoma.
AADAT converts KYN to kynurenic acid, in the process using α ketoglutarate, a key component of TCA) as the
co-substrate. Our preliminary data demonstrates that AADAT single-handedly regulates energy metabolism in
the tumors and immune cell infiltration in the microenvironment potentially mediated via HIF 1α and its
consequent effect on vessel normalization (VN), a homeostatic process involving improved pericyte attachment
to endothelium, increased blood perfusion, de-creased vessel permeability, and consequently reduced hypoxia.
We had earlier demonstrated a novel mutually regulatory loop between VN and immune stimulation in tumor
microenvironment that drove the tumor either into a hot” state with self-reinforcing VN and immune cell
infiltration or into a “cold” state “stuck” with poorly-developed vessels and minimally infiltrated immune cells and
resistant to therapies. Moreover, AADAT depletion also led to activation of IFNγ signaling in cancer cells,
further activating anti-tumor immunity. Based on all of the above, we hypothesize that AADAT promotes cancer
progression and therapeutic resistance by stimulating immune suppression and energy metabolism by
regulating HIF α expression and activity. Our specific aims are: Aim 1: To determine the mechanisms
underpinning AADAT’s immunosuppressive functions in various immunocompetent breast cancer and
melanoma models. Aim 2: Determine mechanism of action of AADAT by modulating intra-tumoral HIF1α
signaling axis. Aim 3 Determine if genetic depletion or pharmacological inhibition of AADAT sensitizes breast
cancer and melanoma to immune checkpoint blockade therapies (ICBT). The impact of our study is to mark
AADAT as a distinct regulator of immune an...

## Key facts

- **NIH application ID:** 9888335
- **Project number:** 5R01CA227904-02
- **Recipient organization:** BAYLOR COLLEGE OF MEDICINE
- **Principal Investigator:** Arun Sreekumar
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $618,327
- **Award type:** 5
- **Project period:** 2019-09-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9888335

## Citation

> US National Institutes of Health, RePORTER application 9888335, Rewired Metabolism Regulates Vessel Normalization and Immunosuppression (5R01CA227904-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9888335. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
